Matthew Wein, who serves as the General Counsel, Compliance Officer, and Corporate Secretary at Metagenomi Therapeutics, Inc. (NASDAQ: MGX), executed a sale of 558 shares of the company's common stock on June 5, 2026. The transaction was processed at a price of $1.299 per share, culminating in a total sale amount of $724. This specific disposition of shares was not a discretionary decision by Wein but was strictly necessitated to satisfy tax withholding obligations associated with the vesting of restricted stock units that were granted to him on April 1, 2024, and April 1, 2025. Consequently, this transaction does not reflect a volitional trade by the executive.
Following the completion of this mandatory sale, Wein's direct ownership in Metagenomi Therapeutics common stock totals 126,491 shares. This aggregate figure incorporates 1,500 shares that were acquired under the company's employee stock purchase plan on May 29, 2026. The execution of this sale occurs against a backdrop of depressed equity valuations for MGX, with the stock trading in close proximity to its 52-week low of $1.21. This current price point marks a substantial 68% decline from the stock's 52-week high of $3.95. Furthermore, the equity has experienced a 7.5% decrease over the preceding week. Valuation analysis from InvestingPro suggests that the company may be undervalued at present levels, citing a Fair Value estimate of $1.79, which places MGX on the most undervalued stocks radar.
In parallel with these insider activity updates, Metagenomi Therapeutics has been the focus of recent analyst commentary. Wells Fargo recently adjusted its price target for the company downward to $9.00 from $12.00, while concurrently maintaining an Overweight rating on the shares. This adjustment by the financial institution coincides with Metagenomi's ongoing development progress for MGX-001, a therapeutic candidate targeting Hemophilia A. The company anticipates filing an Investigational New Drug application in the fourth quarter of 2026, with the initiation of a Phase 1/2 clinical trial expected in 2027. These timelines underscore the company's continued commitment to advancing its clinical pipeline.
Additionally, Metagenomi announced the publication of research in Nature Structural & Molecular Biology that focuses on MG119-28, a compact CRISPR nuclease. The study indicates that MG119-28 exhibits improved genome editing efficiency, attributed to its superior structural stability and more stable guide RNA, which collectively enhance DNA cleavage activity. This advancement in gene editing tools is characterized as a significant development within the field. These concurrent developments highlight Metagenomi's ongoing efforts to advance gene editing technologies while navigating its current market valuation environment.